Nicholas Company Inc. Buys New Shares in Simulations Plus, Inc. (NASDAQ:SLP)

Nicholas Company Inc. acquired a new position in Simulations Plus, Inc. (NASDAQ:SLP - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 122,562 shares of the technology company's stock, valued at approximately $3,418,000. Nicholas Company Inc. owned 0.61% of Simulations Plus as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in SLP. First Horizon Advisors Inc. grew its stake in shares of Simulations Plus by 82.6% in the 3rd quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company's stock worth $26,000 after buying an additional 370 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in Simulations Plus by 53.6% in the fourth quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company's stock worth $34,000 after acquiring an additional 427 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Simulations Plus in the third quarter worth $59,000. AlphaQuest LLC increased its holdings in shares of Simulations Plus by 502.9% during the fourth quarter. AlphaQuest LLC now owns 2,689 shares of the technology company's stock valued at $75,000 after acquiring an additional 2,243 shares in the last quarter. Finally, US Bancorp DE boosted its stake in Simulations Plus by 37.0% in the 3rd quarter. US Bancorp DE now owns 4,974 shares of the technology company's stock worth $159,000 after purchasing an additional 1,343 shares in the last quarter. Institutional investors own 78.08% of the company's stock.

Remove Ads

Insider Buying and Selling

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the transaction, the director now owns 3,402,584 shares of the company's stock, valued at approximately $115,381,623.44. This represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 19.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

SLP has been the subject of several recent analyst reports. KeyCorp lifted their target price on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. William Blair reissued an "outperform" rating on shares of Simulations Plus in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Simulations Plus presently has an average rating of "Moderate Buy" and an average target price of $49.40.

Simulations Plus Stock Performance

Shares of SLP stock traded down $0.83 during trading hours on Thursday, reaching $24.68. The company had a trading volume of 174,264 shares, compared to its average volume of 164,877. The firm has a market cap of $495.87 million, a PE ratio of 61.70 and a beta of 0.89. The business has a fifty day moving average price of $31.42 and a 200-day moving average price of $31.03. Simulations Plus, Inc. has a one year low of $24.00 and a one year high of $51.22.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.